Scholars@Duke publication: Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade.

Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade.

Publication , Conference

Tsao, L-C; Lyerly, HK; Hartman, Z

Published in: CANCER IMMUNOLOGY RESEARCH

April 1, 2020

Link to item

Duke Scholars

Author Herbert Kim Lyerly Surgery, Surgical Sciences

Published In

CANCER IMMUNOLOGY RESEARCH

EISSN

2326-6074

ISSN

2326-6066

Publication Date

April 1, 2020

Volume

Issue

Start / End Page

84 / 84

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

3211 Oncology and carcinogenesis
3204 Immunology
1115 Pharmacology and Pharmaceutical Sciences
1112 Oncology and Carcinogenesis
1107 Immunology

Citation

APA

Chicago

ICMJE

MLA

NLM

Tsao, L.-C., Lyerly, H. K., & Hartman, Z. (2020). Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade. In CANCER IMMUNOLOGY RESEARCH (Vol. 8, pp. 84–84). AMER ASSOC CANCER RESEARCH.

Tsao, Li-Chung, Herbert Kim Lyerly, and Zachary Hartman. “Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade.” In CANCER IMMUNOLOGY RESEARCH, 8:84–84. AMER ASSOC CANCER RESEARCH, 2020.

Tsao L-C, Lyerly HK, Hartman Z. Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade. In: CANCER IMMUNOLOGY RESEARCH. AMER ASSOC CANCER RESEARCH; 2020. p. 84–84.

Tsao, Li-Chung, et al. “Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade.” CANCER IMMUNOLOGY RESEARCH, vol. 8, no. 4, AMER ASSOC CANCER RESEARCH, 2020, pp. 84–84.

Tsao L-C, Lyerly HK, Hartman Z. Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade. CANCER IMMUNOLOGY RESEARCH. AMER ASSOC CANCER RESEARCH; 2020. p. 84–84.

Published In

CANCER IMMUNOLOGY RESEARCH

EISSN

2326-6074

ISSN

2326-6066

Publication Date

April 1, 2020

Volume

Issue

Start / End Page

84 / 84

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

3211 Oncology and carcinogenesis
3204 Immunology
1115 Pharmacology and Pharmaceutical Sciences
1112 Oncology and Carcinogenesis
1107 Immunology